

Anti-IL-1RAP/IL-1R3 Antibody (Nadunolimab)

Introduction B O

Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks the IL1 α and IL1 β signaling pathways and stimulates the immune system to destroy tumor cells. Nidanilimab can be used in the research of non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC).

Product parameters

Alternative Names	Nidanilimab, CAN04
Target Accession	Q9NPH3
Target	IL-1RAP / IL-1R3
CAS number	/
Molecular Weight	144.28 kDa
Host	сно О АРЕхВО
Reactivity	Human Achieve Perfection, Explore the Ustrown
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	-
Isotype	lgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.













APExBIO Technology www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com